Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Lara Elidi"'
Autor:
Chiara Caprioli, Federico Lussana, Silvia Salmoiraghi, Roberta Cavagna, Ksenija Buklijas, Lara Elidi, Pamela Zanghi', Anna Michelato, Federica Delaini, Elena Oldani, Tamara Intermesoli, Anna Grassi, Giacomo Gianfaldoni, Francesco Mannelli, Dario Ferrero, Ernesta Audisio, Elisabetta Terruzzi, Lorella De Paoli, Chiara Cattaneo, Erika Borlenghi, Irene Cavattoni, Monica Tajana, Anna Maria Scattolin, Daniele Mattei, Paolo Corradini, Leonardo Campiotti, Fabio Ciceri, Massimo Bernardi, Elisabetta Todisco, Agostino Cortelezzi, Brunangelo Falini, Chiara Pavoni, Renato Bassan, Orietta Spinelli, Alessandro Rambaldi
Publikováno v:
Haematologica, Vol 106, Iss 10 (2020)
Secondary acute myeloid leukemia (sAML) after myelodysplastic or myeloproliferative disorders is a high-risk category currently identified by clinical history or specific morphological and cytogenetic abnormalities. However, in the absence of these f
Externí odkaz:
https://doaj.org/article/86512554f32e4819856fc359461fbc77
Autor:
Anna Michelato, Fabio Ciceri, Dario Ferrero, Lorella De Paoli, Renato Bassan, Chiara Caprioli, Paolo Corradini, Silvia Salmoiraghi, Brunangelo Falini, Chiara Cattaneo, Giacomo Gianfaldoni, Agostino Cortelezzi, Federica Delaini, Alessandro Rambaldi, Francesco Mannelli, Leonardo Campiotti, Anna Maria Scattolin, Pamela Zanghì, Erika Borlenghi, Federico Lussana, Massimo Bernardi, Ksenija Buklijas, Daniele Mattei, Elena Oldani, Monica Tajana, Tamara Intermesoli, Roberta Cavagna, Anna De Grassi, Irene Cavattoni, Ernesta Audisio, Elisabetta Terruzzi, Orietta Spinelli, Lara Elidi, Elisabetta Todisco, Chiara Pavoni
Publikováno v:
Haematologica
Secondary acute myeloid leukemia (sAML) after myelodysplastic or myeloproliferative disorders is a high-risk category currently identified by clinical history or specific morphological and cytogenetic abnormalities. However, in the absence of these f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b29a752df00892435ddd6e3c36dc4ff
https://doi.org/10.3324/haematol.2020.252825
https://doi.org/10.3324/haematol.2020.252825
Autor:
Renato Bassan, Chiara Pavoni, Pamela Zanghì, Elisabetta Todisco, Nicola Stefano Fracchiolla, Anna Michelato, Leonardo Campiotti, Federico Lussana, Roberta Cavagna, Annamaria Scattolin, Giacomo Gianfaldoni, Chiara Caprioli, Erika Borlenghi, Fabio Ciceri, Ernesta Audisio, Alessandro Rambaldi, Lorella De Paoli, Tamara Intermesoli, Elisabetta Terruzzi, Orietta Spinelli, Ksenija Buklijas, Lara Elidi, Silvia Salmoiraghi, Paola Stefanoni, Paolo Corradini, Daniele Mattei, Irene Cavattoni, Monica Tajana, Elena Oldani
Publikováno v:
Cancers, Vol 12, Iss 2242, p 2242 (2020)
Cancers
Volume 12
Issue 8
Cancers
Volume 12
Issue 8
By way of a Next-Generation Sequencing NGS high throughput approach, we defined the mutational profile in a cohort of 221 normal karyotype acute myeloid leukemia (NK-AML) enrolled into a prospective randomized clinical trial, designed to evaluate an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b10bcb5b62308681575c3159b7c0502b
https://www.mdpi.com/2072-6694/12/8/2242
https://www.mdpi.com/2072-6694/12/8/2242
Autor:
Chiara Caprioli, Dario Ferrero, Monica Tajana, Irene Cavattoni, Leonardo Campiotti, Agostino Cortelezzi, Paolo Corradini, Roberta Cavagna, Annamaria Scattolin, Alberto Bosi, Ksenija Buklijas, Elisabetta Terruzzi, Ernesta Audisio, Silvia Salmoiraghi, Filippo Marmont, Orietta Spinelli, Massimo Bernardi, L De Paoli, Federico Lussana, Federica Delaini, Lara Elidi, Chiara Pavoni, Pamela Zanghì, Renato Bassan, Giuseppe Rossi, Daniele Mattei, Erika Borlenghi, Elisabetta Todisco, Alessandro Rambaldi, Tamara Intermesoli, Elena Oldani, Anna Michelato, Brunangelo Falini, Giacomo Gianfaldoni, Fabio Ciceri, Sergio Cortelazzo
Publikováno v:
HemaSphere. 3:65-66
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da8262fa83bb2be55665f3e8d40dad59
https://doi.org/10.1097/01.hs9.0000559124.85006.27
https://doi.org/10.1097/01.hs9.0000559124.85006.27
Autor:
Elisabetta Todisco, Chiara Pavoni, Daniele Mattei, Federica Delaini, Alessandro Rambaldi, Agostino Cortelezzi, Monica Tajana, Paolo Corradini, Elena Oldani, Federico Lussana, Anna Maria Scattolin, Pamela Zanghì, Chiara Caprioli, Tamara Intermesoli, Brunangelo Falini, Giacomo Gianfaldoni, Elisabetta Terruzzi, Anna Michelato, Orietta Spinelli, Roberta Cavagna, Dario Ferrero, Lara Elidi, Silvia Salmoiraghi, Lorella De Paoli, Renato Bassan, Irene Cavattoni, Ernesta Audisio, Chiara Cattaneo, Fabio Ciceri, Ksenija Buklijas, Filippo Marmont, Leonardo Campiotti, Alberto Bosi, Massimo Bernardi, Erika Borlenghi, Sergio Cortelazzo
Publikováno v:
Blood. 134:1443-1443
Introduction Patients with secondary acute myeloid leukemia (sAML) after myelodysplastic (MDS) or myeloproliferative neoplasms (MPN) treated with chemotherapy show poorer outcomes compared with de novo AML; consequently, these cases should be allocat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0eb823d6a8b0669fbf40a38a357808c
https://doi.org/10.1182/blood-2019-124497
https://doi.org/10.1182/blood-2019-124497